Pernigoni, Nicolò
Guo, Christina
Gallagher, Lewis http://orcid.org/0000-0003-2694-3157
Yuan, Wei
Colucci, Manuel
Troiani, Martina
Liu, Lei
Maraccani, Luisa
Guccini, Ilaria
Migliorini, Denis
de Bono, Johann
Alimonti, Andrea
Article History
Accepted: 15 June 2023
First Online: 25 July 2023
Competing interests
: J.d.B. is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. J.d.B. is an employee of the ICR, and has received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer and Vertex, with a commercial interest in abiraterone, PARP inhibition in DNA repair–defective cancers, and PI3K/AKT pathway inhibitors (no personal income). J.d.B. is an inventor, with no financial interest, on patent 8,822,438 submitted by Janssen, which covers the use of abiraterone acetate with corticosteroids. N.P., M.T. and A.A. are inventors on patent application 102021000021974 submitted by the Institute of Oncology Research (IOR), which covers the use of antibiotics, FMT and probiotics in prostate cancer therapy. D.M. is an inventor on patents related to CAR T cell therapy, filed by the University of Pennsylvania and the University of Geneva, the Università della Svizzera Italiana, and is scientific co-founder of Cellula Therapeutics. D.M. has been a consultant for Limula Therapeutics and MPC Therapeutics. The other authors declare no competing interests.